1. Home
  2. TOVX vs BX Comparison

TOVX vs BX Comparison

Compare TOVX & BX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theriva Biologics Inc.

TOVX

Theriva Biologics Inc.

HOLD

Current Price

$0.23

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Logo Blackstone Inc.

BX

Blackstone Inc.

HOLD

Current Price

$140.77

Market Cap

150.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TOVX
BX
Founded
2001
1985
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
10.1M
150.0B
IPO Year
2012
2007

Fundamental Metrics

Financial Performance
Metric
TOVX
BX
Price
$0.23
$140.77
Analyst Decision
Strong Buy
Buy
Analyst Count
1
17
Target Price
$1.00
$156.53
AVG Volume (30 Days)
439.8K
4.1M
Earning Date
05-13-2026
04-23-2026
Dividend Yield
N/A
3.96%
EPS Growth
89.07
6.91
EPS
N/A
2.37
Revenue
N/A
$14,450,265,000.00
Revenue This Year
N/A
$12.40
Revenue Next Year
N/A
$23.10
P/E Ratio
N/A
$59.32
Revenue Growth
N/A
9.22
52 Week Low
$0.16
$101.73
52 Week High
$0.86
$190.09

Technical Indicators

Market Signals
Indicator
TOVX
BX
Relative Strength Index (RSI) 48.31 58.30
Support Level $0.22 $135.44
Resistance Level $0.26 $149.00
Average True Range (ATR) 0.01 4.57
MACD 0.00 0.27
Stochastic Oscillator 48.07 61.09

Price Performance

Historical Comparison
TOVX
BX

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.

About BX Blackstone Inc.

Blackstone is the world's largest alternative-asset manager with $1.304 trillion in total assets under management, including $937.6 billion in fee-earning assets under management, at the end of March 2026. The company operates with scale in each of its major product lines: private equity (27% of fee-earning AUM and 34% of base management fees), real estate/real assets (30% and 33%), credit and insurance (33% and 26%), and other alternatives (10% and 7%). While the firm primarily serves institutional investors (84% of AUM), it also caters to clients in the high-net-worth channel (16%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).

Share on Social Networks: